Ilyang Pharm Market Cap ($84.55 Million)
Market Cap & Net Worth: Ilyang Pharm (007570)
Ilyang Pharm market cap. Ilyang Pharm (KO:007570) has a market capitalization of $84.55 Million (₩124.76 Billion) as of November 1, 2026. Listed on the KO stock exchange, this Korea-based company holds position #19651 globally and #995 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ilyang Pharm's stock price ₩6960.00 by its total outstanding shares 17924965 (17.92 Million). Also see 007570 operating cash flow for how efficiently the company converts equity into cash flow.
Ilyang Pharm Market Cap History (2015–2026)
Ilyang Pharm market cap history from 2015 to 2026. Data shows change from $580.75 Million to $84.55 Million (-15.94% CAGR). Check latest Ilyang Pharm stock price today for real-time trading data and today's change.
Ilyang Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ilyang Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 007570 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Ilyang Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Ilyang Pharm's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $580.75 Million | $239.26 Billion | $4.41 Billion | 0.00x | 0.13x |
| 2016 | $494.84 Million | $261.61 Billion | $5.91 Billion | 0.00x | 0.08x |
| 2017 | $458.01 Million | $269.81 Billion | $6.26 Billion | 0.00x | 0.07x |
| 2018 | $326.73 Million | $300.04 Billion | -$4.89 Billion | 0.00x | N/A |
| 2019 | $269.39 Million | $324.57 Billion | $9.98 Billion | 0.00x | 0.03x |
| 2020 | $787.61 Million | $343.33 Billion | $10.88 Billion | 0.00x | 0.07x |
| 2021 | $338.18 Million | $371.35 Billion | $14.38 Billion | 0.00x | 0.02x |
| 2022 | $235.05 Million | $383.81 Billion | $19.24 Billion | 0.00x | 0.01x |
| 2023 | $190.11 Million | $266.67 Billion | -$2.41 Billion | 0.00x | N/A |
| 2024 | $138.60 Million | $268.86 Billion | $10.26 Billion | 0.00x | 0.01x |
Competitor Companies of 007570 by Market Capitalization
Companies near Ilyang Pharm in the global market cap rankings as of November 1, 2026. Also see 007570 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Ilyang Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Ilyang Pharm (2015–2026)
Market capitalization of Ilyang Pharm from 2015 to today. Between 2015 and today, Ilyang Pharm's market cap moved from $580.75 Million to $ 84.55 Million, with a yearly change of -15.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩84.55 Million | -46.67% |
| 2025 | ₩158.52 Million | +14.37% |
| 2024 | ₩138.60 Million | -27.09% |
| 2023 | ₩190.11 Million | -19.12% |
| 2022 | ₩235.05 Million | -30.49% |
| 2021 | ₩338.18 Million | -57.06% |
| 2020 | ₩787.61 Million | +192.37% |
| 2019 | ₩269.39 Million | -17.55% |
| 2018 | ₩326.73 Million | -28.66% |
| 2017 | ₩458.01 Million | -7.44% |
| 2016 | ₩494.84 Million | -14.79% |
| 2015 | ₩580.75 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ilyang Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $84.55 Million USD |
| MoneyControl | $84.55 Million USD |
| MarketWatch | $84.55 Million USD |
| marketcap.company | $84.55 Million USD |
| Reuters | $84.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ilyang Pharm
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more